1 Followers
25 Following
RupeshD123

pharmaceuticalhealthcareanalys

Research about healthcare industries

Immuno-oncology Drugs Market - Forecast till 2025

Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer.

Click To Continue Reading on Immuno-oncology Drugs Market

Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to deepened understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immuno-oncology therapies exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy directly target the immune system of the body and does not harm healthy cells in the process, whereas, conventional therapies such as targeted therapy, chemotherapy, and radiation therapy affect cancerous as well as healthy cells extensively.

However, high cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271

Key Vendors:

Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/